BioCentury | May 7, 2015
Distillery Therapeutics

Therapeutics: Glucokinase (GCK; GK); glucokinase regulator (GCKR; GKRP)

...GCK activator, in Phase II testing to treat Type II diabetes. Array BioPharma Inc. has ARRY-403...
BioCentury | Nov 21, 2013
Cover Story

Glucokinase alternative

...disclose their availability for partnering. In August, Amgen discontinued development of its clinical-stage GK activator, ARRY-403...
...Online Intelligence Company Product Development Advinus Therapeutics Ltd. GKM-001 Phase I/II Array BioPharma Inc. (NASDAQ:ARRY) ARRY-403...
BioCentury | Nov 21, 2013
Distillery Therapeutics

Indication: Endocrine/metabolic disease

...to treat type 2 diabetes. In October, Amgen Inc. returned rights to the GK activator ARRY-403...
BioCentury | Aug 12, 2013
Finance

Highlights of weekly biotech stock moves

...2009 deal under which it had rights to Array's small molecule glucokinase activator (GKA) program. AMG 151...
BioCentury | Aug 12, 2013
Company News

Amgen, Array BioPharma deal

...to terminate the deal following a review of a Phase IIa trial with AMG 151 ( ARRY-403...
BioCentury | Aug 7, 2013
Company News

Array cuts headcount, Amgen terminates deal

...GKA) program. All rights to the GKA program will revert to Array, effective Oct. 5. AMG 151...
BioCentury | Jul 23, 2012
Finance

Highlights of weekly biotech stock moves

...triggered by Amgen reaching pre-defined patient enrollment criteria in a Phase IIa diabetes trial of AMG 151...
BioCentury | Jul 23, 2012
Company News

Amgen, Array BioPharma deal

...was triggered by Amgen reaching pre-defined patient enrollment in a U.S. Phase IIa trial evaluating AMG 151...
BioCentury | Aug 22, 2011
Strategy

Checkpoint match

...worldwide rights to its small molecule glucokinase ( GCK ; GK ) activator program, including ARRY-403...
BioCentury | Apr 26, 2010
Strategy

Ready to graduate

...Array granted Amgen exclusive, worldwide rights to a small molecule glucokinase activator (GKA) program, including ARRY-403...
Items per page:
1 - 10 of 19